Randomized trial · people
Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 1 diabetes and obesity on automated insulin delivery, adding semaglutide improved time in range and weight over 26 weeks, with the same number of severe lows as placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 72
- Published
- 2025
- Journal
- NEJM Evid
What they tested
The team tested whether weekly semaglutide helps adults with type 1 diabetes and obesity who already use an automated insulin delivery system reach blood sugar and weight goals.
How the study was done
A randomized, double-blind, placebo-controlled trial in 72 adults with type 1 diabetes, a body mass index of 30 or higher, and an automated insulin delivery (AID) system, a pump linked to a glucose sensor. For 26 weeks, they got weekly semaglutide up to 1 mg or placebo, a dummy shot.

Model. Individual results vary.
What they found
To meet the main goal, a person needed more than 70% of the time with glucose between 70 and 180 mg/dl on a continuous glucose monitor (CGM, a wearable sensor), less than 4% of the time below 70 mg/dl, and at least 5% weight loss. 36% of the semaglutide group met every part, compared with 0% on placebo (P<0.001). Compared with placebo, the semaglutide group changed by -0.3 percentage points in glycated hemoglobin (HbA1c, a longer-term average of blood sugar), gained 8.8 percentage points of time in the 70 to 180 mg/dl range, and changed by -8.8 kg in body weight. Each group had two severe low blood sugar events, and there was no diabetic ketoacidosis.
What it doesn’t show
This was a small, 26-week trial, so it can't show longer-term effects or rarer side effects. Everyone used an AID system, so the result may not apply to people with type 1 diabetes on other insulin setups.
The paper
Shah et al. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.